ArticleCureus2025
Argon Laser Phototherapy as an Adjunctive Treatment for Refractory Fungal Keratitis: A Retrospective Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aimed to evaluate the safety and clinical efficacy of argon laser phototherapy (ALP) as an adjunctive treatment for refractory fungal keratitis (FK) in a retrospective case series. Methodology This retrospective case series included 10 eyes from 10 patients with culture-proven FK that failed to improve after ≥2 weeks of topical antifungals. All eyes underwent adjunctive ALP (532 nm, 200 µm, 0.1 seconds, 900-1200 mW) applied to the fluorescein-stained ulcer bed until mild stromal blanching/microcavitation was observed. Standard topical antifungals were continued thereafter. The primary outcome was the time to complete epithelial healing with resolution of stromal infiltration. Secondary outcomes were the change in best-corrected visual acuity (BCVA) and adverse events. Minimum follow-up was three months. Results The mean age of the patients was 48.2 ± 11.6 years. Causative organisms included
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.